Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma

BACKGROUND: Surgery is the primary treatment for basal cell carcinoma (BCC). In locally advanced basal cell carcinoma (laBCC), surgery may cause functional or aesthetic damage. In laBCC, neoadjuvant administration of vismodegib, an inhibitor of the Hedgehog signaling pathway, may reduce tumor size,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EClinicalMedicine
Main Authors: Bertrand, Nicolas, Guerreschi, Pierre, Basset-Seguin, Nicole, Saiag, Philippe, Dupuy, Alain, Dalac-Rat, Sophie, Dziwniel, Véronique, Depoortère, César, Duhamel, Alain, Mortier, Laurent
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Research paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8093898/
https://ncbi.nlm.nih.gov/pubmed/33997740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100844
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados